CD8+ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity
- 1 January 2015
- journal article
- review article
- Published by Begell House Inc. Publishers in Critical Reviews in Immunology
- Vol. 35 (2) , 153-172
Abstract
Despite the growing number of preclinical and clinical trials focused on immunotherapy for the treatment of malignant gliomas, the prognosis for this disease remains grim. Cancer immunotherapy seeks to recruit an effective immune response to eliminate tumor cells. To date, cancer vaccines have shown only limited effectiveness because of our incomplete understanding of the necessary effector cells and mechanisms that yield efficient tumor clearance. CD8+ T cell cytotoxic activity has long been proposed as the primary effector function necessary for tumor regression. However, there is increasing evidence that indicates that components of the immune system other than CD8+ T cells play important roles in tumor eradication and control. The following review should provide an understanding of the mechanisms involved in an effective antitumor response to guide future therapeutic designs. The information provided suggests an alternate means of effective tumor clearance in malignant glioma to the canonical CD8+ cytotoxic T cell mechanism.Keywords
This publication has 100 references indexed in Scilit:
- T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor ImmunityImmunity, 2009
- CD4 T Cells Mediate Killing during Persistent Gammaherpesvirus 68 InfectionJournal of Virology, 2009
- Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activationHuman Immunology, 2009
- Follicular Helper T Cells: Lineage and LocationImmunity, 2009
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphomaBlood, 2008
- Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-α2Cancer Research, 2008
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- Chapter 8 The Role of NKT Cells in Tumor Immunity2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005